Intersect ENT (NSDQ:XENT) today posted first quarter earnings that topped sales expectations but missed loss-per-share consensus on Wall Street.
The Menlo Park, Calif.-based company posted losses of $10.8 million, or 35¢ per share, on sales of $26.7 million for the three months ended March 31, seeing losses grow 76.1% while sales grew 7.9% compared with the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business News